Johnniegalan “while locking in insurance companies to exclusively use V”….how do know this? I hope you are correct on the “locked in” part….locked in by contract?…”
In previous presentations KM mention getting IIRC 40% of payers to agree to cover V exclusively for their Pts. Those deals likely 1 year contracts to be renegotiated each year. With more generics fighting for the market prices would have become more competitive and from what Duke reports it appears several have switched over to the generics for 2023.
The distributors would be the wholesalers (eg AmerisourceBergen) who buy from Amarin and distribute to all the pharmacies nationwide. Those contracts would be pretty basic and not altered by the presence of generics.
It would appear quite clear that Method of Use patents are completely worthless in the US as KM did sound quite resolved to the fact the US market could only be maintained by making deals with insurance companies. Insurance companies have way too much power in the healthcare system. They force doctors, pharmacists, and Pts to do exactly what they say and can prevent any of them from doing what is best for the pt just as easily.
Market Data 
Markets 
AI
